APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume

African American–Diabetes Heart Study MIND (AA-DHS MIND) and Systolic Blood Pressure Intervention Trial (SPRINT) Research Groups

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To assess apolipoprotein L1 gene (APOL1) renal-risk-variant effects on the brain, magnetic resonance imaging (MRI)-based cerebral volumes and cognitive function were assessed in 517 African American–Diabetes Heart Study (AA-DHS) Memory IN Diabetes (MIND) and 2568 hypertensive African American Systolic Blood Pressure Intervention Trial (SPRINT) participants without diabetes. Within these cohorts, 483 and 197 had cerebral MRI, respectively. AA-DHS participants were characterized as follows: 60.9% female, mean age of 58.6 years, diabetes duration 13.1 years, estimated glomerular filtration rate of 88.2 ml/min/1.73 m2, and a median spot urine albumin to creatinine ratio of 10.0 mg/g. In additive genetic models adjusting for age, sex, ancestry, scanner, intracranial volume, body mass index, hemoglobin A1c, statins, nephropathy, smoking, hypertension, and cardiovascular disease, APOL1 renal-risk-variants were positively associated with gray matter volume (β = 3.4 × 10–3) and negatively associated with white matter lesion volume (β = –0.303) (an indicator of cerebral small vessel disease) and cerebrospinal fluid volume (β= –30707) (all significant), but not with white matter volume or cognitive function. Significant associations corresponding to adjusted effect sizes (β/SE) were observed with gray matter volume (0.16) and white matter lesion volume (–0.208), but not with cerebrospinal fluid volume (–0.251). Meta-analysis results with SPRINT Memory and Cognition in Decreased Hypertension (MIND) participants who had cerebral MRI were confirmatory. Thus, APOL1 renal-risk-variants are associated with larger gray matter volume and lower white matter lesion volume suggesting lower intracranial small vessel disease.

Original languageEnglish (US)
Pages (from-to)440-449
Number of pages10
JournalKidney International
Volume90
Issue number2
DOIs
StatePublished - Aug 1 2016

Fingerprint

Apolipoproteins
Cognition
Blood Pressure
Kidney
Magnetic Resonance Imaging
Genes
Cerebrospinal Fluid
Cerebral Small Vessel Diseases
Hypertension
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Genetic Models
Glomerular Filtration Rate
African Americans
Meta-Analysis
Albumins
Creatinine
Hemoglobins
Body Mass Index
Cardiovascular Diseases
Smoking

Keywords

  • African Americans
  • APOL1
  • brain
  • cognition
  • hypertension
  • magnetic resonance imaging
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Medicine(all)
  • Nephrology

Cite this

African American–Diabetes Heart Study MIND (AA-DHS MIND) and Systolic Blood Pressure Intervention Trial (SPRINT) Research Groups (2016). APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. Kidney International, 90(2), 440-449. https://doi.org/10.1016/j.kint.2016.04.027

APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. / African American–Diabetes Heart Study MIND (AA-DHS MIND) and Systolic Blood Pressure Intervention Trial (SPRINT) Research Groups.

In: Kidney International, Vol. 90, No. 2, 01.08.2016, p. 440-449.

Research output: Contribution to journalArticle

African American–Diabetes Heart Study MIND (AA-DHS MIND) and Systolic Blood Pressure Intervention Trial (SPRINT) Research Groups 2016, 'APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume', Kidney International, vol. 90, no. 2, pp. 440-449. https://doi.org/10.1016/j.kint.2016.04.027
African American–Diabetes Heart Study MIND (AA-DHS MIND) and Systolic Blood Pressure Intervention Trial (SPRINT) Research Groups. APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. Kidney International. 2016 Aug 1;90(2):440-449. https://doi.org/10.1016/j.kint.2016.04.027
African American–Diabetes Heart Study MIND (AA-DHS MIND) and Systolic Blood Pressure Intervention Trial (SPRINT) Research Groups. / APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. In: Kidney International. 2016 ; Vol. 90, No. 2. pp. 440-449.
@article{0df0217969af47be898163768fd52bd4,
title = "APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume",
abstract = "To assess apolipoprotein L1 gene (APOL1) renal-risk-variant effects on the brain, magnetic resonance imaging (MRI)-based cerebral volumes and cognitive function were assessed in 517 African American–Diabetes Heart Study (AA-DHS) Memory IN Diabetes (MIND) and 2568 hypertensive African American Systolic Blood Pressure Intervention Trial (SPRINT) participants without diabetes. Within these cohorts, 483 and 197 had cerebral MRI, respectively. AA-DHS participants were characterized as follows: 60.9{\%} female, mean age of 58.6 years, diabetes duration 13.1 years, estimated glomerular filtration rate of 88.2 ml/min/1.73 m2, and a median spot urine albumin to creatinine ratio of 10.0 mg/g. In additive genetic models adjusting for age, sex, ancestry, scanner, intracranial volume, body mass index, hemoglobin A1c, statins, nephropathy, smoking, hypertension, and cardiovascular disease, APOL1 renal-risk-variants were positively associated with gray matter volume (β = 3.4 × 10–3) and negatively associated with white matter lesion volume (β = –0.303) (an indicator of cerebral small vessel disease) and cerebrospinal fluid volume (β= –30707) (all significant), but not with white matter volume or cognitive function. Significant associations corresponding to adjusted effect sizes (β/SE) were observed with gray matter volume (0.16) and white matter lesion volume (–0.208), but not with cerebrospinal fluid volume (–0.251). Meta-analysis results with SPRINT Memory and Cognition in Decreased Hypertension (MIND) participants who had cerebral MRI were confirmatory. Thus, APOL1 renal-risk-variants are associated with larger gray matter volume and lower white matter lesion volume suggesting lower intracranial small vessel disease.",
keywords = "African Americans, APOL1, brain, cognition, hypertension, magnetic resonance imaging, type 2 diabetes mellitus",
author = "{African American–Diabetes Heart Study MIND (AA-DHS MIND) and Systolic Blood Pressure Intervention Trial (SPRINT) Research Groups} and Freedman, {Barry I.} and Gadegbeku, {Crystal A.} and Bryan, {R. Nick} and Palmer, {Nicholette D.} and Hicks, {Pamela J.} and Lijun Ma and Rocco, {Michael V.} and Smith, {S. Carrie} and Jianzhao Xu and Whitlow, {Christopher T.} and Wagner, {Benjamin C.} and Langefeld, {Carl D.} and Hawfield, {Amret T.} and Bates, {Jeffrey T.} and Lerner, {Alan J.} and Raj, {Dominic S.} and Sadaghiani, {Mohammad S.} and Toto, {Robert D} and Wright, {Jackson T.} and Bowden, {Donald W.} and Williamson, {Jeff D.} and Sink, {Kaycee M.} and Maldjian, {Joseph A} and Pajewski, {Nicholas M.} and Jasmin Divers",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.kint.2016.04.027",
language = "English (US)",
volume = "90",
pages = "440--449",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume

AU - African American–Diabetes Heart Study MIND (AA-DHS MIND) and Systolic Blood Pressure Intervention Trial (SPRINT) Research Groups

AU - Freedman, Barry I.

AU - Gadegbeku, Crystal A.

AU - Bryan, R. Nick

AU - Palmer, Nicholette D.

AU - Hicks, Pamela J.

AU - Ma, Lijun

AU - Rocco, Michael V.

AU - Smith, S. Carrie

AU - Xu, Jianzhao

AU - Whitlow, Christopher T.

AU - Wagner, Benjamin C.

AU - Langefeld, Carl D.

AU - Hawfield, Amret T.

AU - Bates, Jeffrey T.

AU - Lerner, Alan J.

AU - Raj, Dominic S.

AU - Sadaghiani, Mohammad S.

AU - Toto, Robert D

AU - Wright, Jackson T.

AU - Bowden, Donald W.

AU - Williamson, Jeff D.

AU - Sink, Kaycee M.

AU - Maldjian, Joseph A

AU - Pajewski, Nicholas M.

AU - Divers, Jasmin

PY - 2016/8/1

Y1 - 2016/8/1

N2 - To assess apolipoprotein L1 gene (APOL1) renal-risk-variant effects on the brain, magnetic resonance imaging (MRI)-based cerebral volumes and cognitive function were assessed in 517 African American–Diabetes Heart Study (AA-DHS) Memory IN Diabetes (MIND) and 2568 hypertensive African American Systolic Blood Pressure Intervention Trial (SPRINT) participants without diabetes. Within these cohorts, 483 and 197 had cerebral MRI, respectively. AA-DHS participants were characterized as follows: 60.9% female, mean age of 58.6 years, diabetes duration 13.1 years, estimated glomerular filtration rate of 88.2 ml/min/1.73 m2, and a median spot urine albumin to creatinine ratio of 10.0 mg/g. In additive genetic models adjusting for age, sex, ancestry, scanner, intracranial volume, body mass index, hemoglobin A1c, statins, nephropathy, smoking, hypertension, and cardiovascular disease, APOL1 renal-risk-variants were positively associated with gray matter volume (β = 3.4 × 10–3) and negatively associated with white matter lesion volume (β = –0.303) (an indicator of cerebral small vessel disease) and cerebrospinal fluid volume (β= –30707) (all significant), but not with white matter volume or cognitive function. Significant associations corresponding to adjusted effect sizes (β/SE) were observed with gray matter volume (0.16) and white matter lesion volume (–0.208), but not with cerebrospinal fluid volume (–0.251). Meta-analysis results with SPRINT Memory and Cognition in Decreased Hypertension (MIND) participants who had cerebral MRI were confirmatory. Thus, APOL1 renal-risk-variants are associated with larger gray matter volume and lower white matter lesion volume suggesting lower intracranial small vessel disease.

AB - To assess apolipoprotein L1 gene (APOL1) renal-risk-variant effects on the brain, magnetic resonance imaging (MRI)-based cerebral volumes and cognitive function were assessed in 517 African American–Diabetes Heart Study (AA-DHS) Memory IN Diabetes (MIND) and 2568 hypertensive African American Systolic Blood Pressure Intervention Trial (SPRINT) participants without diabetes. Within these cohorts, 483 and 197 had cerebral MRI, respectively. AA-DHS participants were characterized as follows: 60.9% female, mean age of 58.6 years, diabetes duration 13.1 years, estimated glomerular filtration rate of 88.2 ml/min/1.73 m2, and a median spot urine albumin to creatinine ratio of 10.0 mg/g. In additive genetic models adjusting for age, sex, ancestry, scanner, intracranial volume, body mass index, hemoglobin A1c, statins, nephropathy, smoking, hypertension, and cardiovascular disease, APOL1 renal-risk-variants were positively associated with gray matter volume (β = 3.4 × 10–3) and negatively associated with white matter lesion volume (β = –0.303) (an indicator of cerebral small vessel disease) and cerebrospinal fluid volume (β= –30707) (all significant), but not with white matter volume or cognitive function. Significant associations corresponding to adjusted effect sizes (β/SE) were observed with gray matter volume (0.16) and white matter lesion volume (–0.208), but not with cerebrospinal fluid volume (–0.251). Meta-analysis results with SPRINT Memory and Cognition in Decreased Hypertension (MIND) participants who had cerebral MRI were confirmatory. Thus, APOL1 renal-risk-variants are associated with larger gray matter volume and lower white matter lesion volume suggesting lower intracranial small vessel disease.

KW - African Americans

KW - APOL1

KW - brain

KW - cognition

KW - hypertension

KW - magnetic resonance imaging

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84992520139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992520139&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2016.04.027

DO - 10.1016/j.kint.2016.04.027

M3 - Article

VL - 90

SP - 440

EP - 449

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -